Table 3.
Clinical demographics of refractory pouch inflammation cohort according to whether the patients had infliximab treatment or no biologic treatment.
| Feature | Infliximab cohort (n = 42) | Responders (n = 26) | Non-responders (n = 16) | No infliximab cohort (n = 110) | CP (n = 60) | CDL (n = 50) | p-value |
|---|---|---|---|---|---|---|---|
| Gender, n (% male) | 11 (25) | 7 (25) | 4 (25) | 54 (51) | 33 (55) | 22 (44) | 0.01 |
| Duration from UC diagnosis to surgery (y, SD) | 5.2 (4.2) | 3.6 (4.3) | 5.6 (5.0) | 6.8 (6.9) | 7.2 (6.7) | 6.2 (7.5) | 0.13 |
| Age at diagnosis (y, median) | 24 | 21 | 25 | 29 | 29 | 29 | 0.67 |
| Age at surgery (y, median) | 32 | 25 | 33 | 37 | 37 | 36 | 0.45 |
| UC extent pre-operation (%) | 0.29 | ||||||
| E1 | 0 | 0 | 0 | 1.9 | 0 | 2 | |
| E2 | 17 | 15.3 | 18.75 | 6.3 | 10 | 4 | |
| E3 | 83 | 84.6 | 81.25 | 91.8 | 90 | 94 | |
| Family history IBD (%) | 6 (14.8) | 3 | 3 | 22 (19) | 13 | 9 | 0.3 |
| Smoking status | 0.03 | ||||||
| Never smoked (%) | 18 | 12 | 6 | 41.8 | 46.6 | 36 | |
| Ex-smoker (%) | 13 | 7 | 6 | 46.3 | 46.6 | 46 | |
| Current smoker (%) | 11 (26) | 4 | 7 | 11.9 | 6.7 | 18 | |
| Extra-intestinal manifestations (%) | 19 | 11.5 | 31 | 21 | 16.6 | 26 | 0.9 |
| PSC (%) | 0 | 0 | 0 | 5.4 | 6.6 | 4 | 0.17 |
CDL, Crohn’s disease-like phenotype; CP, chronic refractory pouchitis; IBD, inflammatory bowel disease; PSC, primary sclerosing cholangitis; UC, ulcerative colitis.